LTR Pharma Limited

LTP Secures Global Co-Development Agreement with Aptar Pharma

LTR Pharma Limited (ASX:LTR) (“LTR Pharma”, “the Company”) is pleased to announce that it has entered into a Co-Development Agreement (“the Agreement”) for SPONTAN for global markets.


Highlights:

  • LTR Pharma (ASX:LTP) and Aptar Pharma have entered into a Co-Development Agreement for SPONTAN® for global markets.
  • The primary goal is commercialisation of SPONTAN in the USA and other key markets.
  • The Agreement will combine LTP’s pharmaceutical development capabilities with Aptar Pharma’s expertise in nasal spray technology, supporting a streamlined regulatory pathway and market access for SPONTAN.
The Agreement has been secured with Aptar Pharma https://aptar.com/pharmaceutical/, a global leader in drug delivery systems, services and active material science solutions. Aptar Pharma has supported numerous market authorisation holders in obtaining their combination drug-device product approvals incorporating Aptar’s nasal delivery systems from regulatory agencies such as the U.S. Food and Drug Administration (FDA).

The Agreement will encompass joint development and expertise, combining LTR Pharma's pharmaceutical development capabilities with Aptar Pharma's expertise in nasal spray technology – including Aptar’s VP7 model nasal spray components. The application for SPONTAN Nasal Spray will be filed in the US via the FDA’s 505(b)(2) expedited regulatory pathway, which governs a change in route of administration of an already approved drug, here Levitra® (Vardenafil) tablets.

The Agreement grants LTR Pharma access to Aptar Pharma’s comprehensive range of regulatory, analytical testing, and human factor services, which will considerably strengthen the FDA application process for SPONTAN.

A shared goal will be to focus on imminent market establishment and expansion, targeting commercialisation in the USA, and other key global markets – together with a long-term strategic alliance for ongoing innovation for healthcare solutions.

LTR Pharma Chairman, Lee Rodne, said:

“We are delighted to enter into a Co-Development Agreement with Aptar Pharma – a respected and experienced partner in our imminent goal to obtain regulatory approval for SPONTAN and to expand its global market reach and impact. As part of this, we will gain access to Aptar’s expertise in the VP7 nasal spray system and related specialised services to support our FDA application process. This vastly de-risks the FDA application process and elevates the profile of LTR Pharma as a long-term partner of a global market innovator, which we anticipate may create opportunities for other products with alternative indications in future.”

Guillaume Brouet, Vice President Analytical Regulatory and Scientific Affairs Aptar Pharma, said:

“We look forward to working closely alongside the LTR Pharma team to support its SPONTAN Nasal Spray application. We have purpose-designed facilities and experienced personnel to ensure a successful partnership throughout this Co- Development– within an efficient timeframe.”

LTP recently completed its clinical trial to compare the pharmacokinetics, safety, and tolerability of Vardenafil following administration of SPONTAN nasal spray and Levitra® tablets in healthy male adults. The trial showed that SPONTAN achieved a rapid absorption and faster onset of action compared to oral PDE5 inhibitors (i.e., vardenafil, sildenafil, tadalafil) and delivered a similar amount of drug (Cmax) at half the dose of the oral PDE5 tablet. Following the success of this clinical trial, medical providers have started prescribing SPONTAN in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).


Click here for the full ASX Release

This article includes content from LTR Pharma Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News